Special article

Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. II: CAR-T cell therapy for patients with CD19+ acute lymphoblastic leukemia

Adriana Seber a,b, Claudio Galvão de Castro Junior c,d, Lucila N. Kerbauy e, Alexandre V. Hirayama f, Carmem Bonfim g,h, Juliana Folloni Fernandes e,i, Mair Souza j, Rony Schafel k, Samir Nabhan l, Sandra Regina Loggetto b,m, Belinda Pinto Simões n, Vanderson Rocha b,p, Marcos de Lima q, Renato L. Guerino-Cunha r,*, Henrique Bittencourt s,t

a Hospital Samaritano Higienópolis, São Paulo, SP, Brazil
b Hospital Infantil Sabará, São Paulo, SP, Brazil
c Hemomed Instituto de Oncologia e Hematologia, São Paulo, SP, Brazil
d Hospital São Camilo, São Paulo, SP, Brazil
e Hospital Israelita Albert Einstein, São Paulo, SP, Brazil
f Fred Hutchinson Cancer Research Center, Seattle, WA, EUA
g Hospital Pequeno Príncipe, Curitiba, PR, Brazil
h Hospital de Clínicas, Universidade Federal do Paraná (HC UFPR), Curitiba, PR, Brazil
i Instituto do Tratamento do Câncer Infantil, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HC FMUSP), São Paulo, SP, Brazil
j Hospital Amaral Carvalho, Jaú, SP, Brazil
k Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro (HUCFF UFRJ), Rio de Janeiro, RJ, Brazil
l Hospital de Clínicas - Universidade Federal do Paraná, (HC UFPR), Curitiba, PR, Brazil
m Grupo Gestor de Serviços de Hematologia (GSH), São Paulo, SP, Brazil
n Kolb Consulting UC, Munich, Germany
o Hospital das Clínicas, Universidade de São Paulo, (HC USP), São Paulo, SP, Brazil
p Hospital Vila Nova Star, São Paulo, SP, Brazil
q Ohio State University, Columbus, OH, USA
r Faculty of Medicine of Ribeirão Preto, Universidade de São Paulo (FMRP-USP), Ribeirão Preto, SP, Brazil
s Centre Hospitalier Universitaire Sainte-Justine (CHU Sainte-Justine), Montreal, QC, Canada
t Université de Montréal, Montreal, QC, Canada

* Corresponding author at: Departamento de Imagens Médicas, Hematologia e Oncologia Clínica da Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo (FMRP-USP), Rua Tenente Catiao Roxo, 2501, Vila Monte Alegre, Ribeirão Preto, SP, Brazil.
E-mail address: rlgc@usp.br (R.L. Guerino-Cunha).

https://doi.org/10.1016/j.htct.2021.09.002

2531-1379/© 2021 Published by Elsevier España, S.L.U. on behalf of Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction

Acute lymphoblastic leukemia (ALL) is the most prevalent cancer among children. Intensive chemotherapy protocols offer cure to most of them. However, patients who develop refractory disease or early medullary relapse have a grim prognosis. According to the Brazilian National Cancer Institute, 524 children between 0 and 19 years of age died due to ALL in the country in 2019, whereas the number of adult deaths in the same year was 1,710 (supplementary material).

Despite important advances in clinical support to these patient population, the mortality rate of patients with ALL has not significantly decreased in our country in the last 15 years. The toxicities related to chemotherapy undermine any potential benefit with an increase in the treatment intensity. In this context, immunotherapy against different antigens on the leukemic cell surface has revolutionized the ALL treatment with significantly decrease in the toxicities compared to conventional chemotherapy.

Currently, three immunotherapy modalities have been approved for clinical use in B-cell lineage ALL (B-ALL) in North America and Europe: an anti-CD22 antibody linked to calicheamicin (inotuzumab ozogamicin), a bispecific anti-CD3 and anti-CD19 antibody (blinatumomab) and an anti-CD19 chimeric antigen receptor T (CAR-T) cell product. The effect of inotuzumab depends on the calicheamicin, a chemotherapeutic agent with the capacity of inducing apoptosis of the target cells. The CD22 antigen has a slightly more restricted expression than CD19 in B-ALL, which may limit its use in some cases. Blinatumomab exerts an antileukemic effect upon engaging the patient’s normal T cells against leukemic CD19+ cells. Its use as a monotherapy or, more recently, in association with chemotherapy (in pediatric patients in first early relapse) is associated with complete remission (CR) and minimal residual disease (MRD) negative rates that are superior to those of chemotherapy alone. For patients who have reached CR with negative MRD, consolidation with an allogeneic hematopoietic stem cell transplant (HSCT) is recommended. Each blinatumomab cycle lasts 28 days of continuous infusion, making the logistics of administration quite complex. In this context, the most recent and promising technology involves the genetic modification of autologous T cells, the CAR-T cells, to recognize and destroy cells of leukemic origin. This therapy results in high rates of MRD-negative CR. Considering the imminent approval of some commercial anti-CD19 CAR-T cell products by the Agência Nacional de Vigilância Sanitária (ANVISA), the Brazilian Association of Hematology, Hemotherapy and Cellular Therapy (ABHH) invited a panel of specialists in hematological neoplasms, cellular therapy and HSCT to elaborate recommendations for this new treatment modality for B-ALL patients in Brazil.

In this manuscript, we describe practical recommendations with the objective of guide the selection of patients who will undergo anti-CD19 CAR-T cell therapy, as well as the evaluation and management pre- and post-infusion in the Brazilian scenario.

Indications

The use of CAR-T cells for the treatment of patients with B-ALL results in high response rates in patients with relapsed or refractory (R/R) disease. The first, and to date the only, product approved for commercialization by the American and European medication control agencies, namely, the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of patients with B-ALL is tisagenlecleucel (KYMRIAH; Novartis Pharmaceuticals Corp.), an autologous anti-CD19 CAR-T cell containing the 4-1BB as co-stimulatory molecule. This approval was based on the results of the multicentric phase 2 study ELIANA, which demonstrated a MRD-negative CR in 81% of the pediatric and young adult patients treated and an overall survival (OS) of 76% at 12 months. With the development of new cellular therapy products involving other types of cells and/or target antigens, indications and patient eligibility for CAR-T cell treatments will be adapted for each new product in accordance with the results of clinical trials. The current scenario allows for some considerations:

- For tisagenlecleucel, the indication approved by the EMA includes pediatric and young adult patients up to 25 years of age with refractory B-ALL, relapsed after HSCT or in the second or subsequent relapse. Regarding the FDA, the
approved indication is also for patients up to 25 years of age and refractory ALL or after the second relapse.12

• In the Brazilian scenario, the present panel of specialists points out that CAR-T cell therapy is currently recognized as a salvage therapy and, therefore, recommends that its indication should be for pediatric and young adult patients up to 25 years of age with refractory disease (primary or following the first relapse), in the second relapse, or relapsed after HSCT.

• The presence of leukemic infiltration in the central nervous system (CNS) does not contraindicate treatment with CAR-T cells.13,14 There is already data demonstrating the acceptable safety of the treatment with tisagenlecleucel in patients with secondary involvement of the CNS by lymphoma.15 However, this information does not appear in the FDA or EMA recommendations8,9 and patients with CNS infiltration should be followed closely after infusion, given the greater risk for neurotoxicity.16

• The expression of the target antigen (CD19) in the leukemic cell must be evaluated and confirmed by flow cytometry. Preferably, the antigen expression rates should be expressed as a percentage of total positive blasts. In the case of products involving other targets, the same rationale is applicable.

Treatment of R/R B-ALL in patients older than 26 years of age continues to be an unmet clinical need, given the absence of products commercially available at the moment of the elaboration of this consensus. The recent published results of the phase 2 international multicentric study ZUMA-3 evaluating the use of KTE-X19 (an autologous anti-CD19 CAR-T cell which contains the CD28 as co-stimulatory molecule recently approved for mantle cell lymphoma) in adults with R/R B-ALL signalizes that this product will be available for this patient population soon. The ZUMA-3 study included patients 18 years of age or older and demonstrated a CR or CR with incomplete hematological recovery (CRi) rate of 70.9%, with MRD-negative in 97% of the responding patients. The median OS was 18.2 months.17

Patient selection, logistics and pre-infusion evaluation and management before CAR-T cells

Pre-apheresis

The decision to treat a patient with CAR-T cells should be coordinated by the clinical team responsible for the infusion/treatment of the patient and the team manufacturing the CAR-T cells. In addition, specialized and multidisciplinary evaluation is imperative. The patient must have the minimum necessary clinical conditions to receive this high-cost therapy, avoiding its use in situations of short life expectancy. Additionally, most patients require bridging therapy to control the tumor burden during the period of manufacturing of the CAR-T cells, which also requires the coordinated efforts of the teams.

Once established the indication of the patient with B-ALL to receive anti-CD19 CAR-T cell therapy, it is important to define the approach to manage each of the phases of the process (apheresis, lymphodepletion and infusion of the CAR-T cells). At this moment, it is recommended, by well validated and defined operational procedures, that the following line of care be established:

• The referring physician must contact the cellular therapy team to discuss the patient eligibility to receive the treatment and to organize the logistics aspects. It is important to estimate the time between the apheresis and the receipt of the final product (CAR-T cells) by the center responsible for the infusion;

• At the same time, discuss the patient eligibility for bridging therapy to be initiated after the collection of T-cells by apheresis;

• The referral to the center for the collection and manufacturing of CAR-T cells should be performed by means of a specific form that contains the clinical and laboratory information relevant to the clinical condition of the patient.

The previous use of blinatumomab and inotuzumab ozogamicin should be discussed and considered in the treatment strategy of patients eligible for CAR-T cell therapy.

Blinatumomab is a bispecific antibody that recruits T-cells against CD19 positive cells with a mechanism of action similar to that of the anti-CD19 CAR-T cells. Thus, previous use of blinatumomab should be considered in the indication for CAR-T cell therapy due to reports of decreased CAR-T cell efficacy.18 In patients previously exposed to blinatumomab, it is important to check for the presence of a CD19-negative clone by flow cytometry, even before the indication for apheresis, which might be associated with escape after therapy with anti-CD19 CAR-T cells. In the case there is no expression of CD19 in the blasts, anti-CD19 CART-T cell should not be indicated.19 Decrease in the expression of CD19 in the blasts, following the use of blinatumomab, is associated with inferior outcomes of CAR-T cell therapy when compared to patients who had not used blinatumomab.18,20 Data on the previous use of inotuzumab ozogamicin indicate that its use may be associated with a lower expansion of CAR-T cells, however, this requires further validation.20 Currently, there is no anti-CD22 CAR-T cell product approved by any regulatory agency for use in clinical practice.21

In primarily refractory patients, i.e. those who fail to achieve MRD-negative CR, the sequential use of blinatumomab and CAR-T cells is not recommended, although frequently cannot be avoided. In the case of patients in relapse, blinatumomab should be avoided in the case that treatment with anti-CD19 CAR-T cells is being considered.

Apheresis

The evaluation of the number of circulating lymphocytes or T-cells is important for planning the apheresis (a minimum of 500 total lymphocytes/mm3 and/or 150 CD3+ lymphocytes/mm3 is recommended, although apheresis can be performed with lower counts).12,22 For patients previously submitted to HSCT, it is recommended the absence of acute or chronic graft versus host disease (GVHD) in activity before the apheresis and infusion of the CAR-T cells.24 A period without
chemotherapy and immunosuppressants, variable according to the medication, is also recommended before apheresis and the infusion of the CAR-T cells (Table 1).

Moreover, it is essential for the patient not to have an active infection before each stage of the treatment, as this increases the risk of contamination of the apheresis product and of CRS after infusion. Likewise, evaluation of comorbidities and toxicities in target organs (heart, kidneys, liver, and lungs) prior to CAR-T cell therapy is fundamental, as it can contraindicate the therapy. On the other hand, it is important to weigh the risk of toxicity related to the comorbidities versus the risk of alternate treatments for leukemia and the risk of CRS. A practical example is the presence of a moderate hepatic toxicity in a patient with a low leukemic burden. This patient will probably experience greater toxicity if he or she undergoes HSCT than that of being submitted to CAR-T cell therapy.

It is important to highlight that in the multicentric trial ELIANA the incidence of manufacturing failure, which is the failure of producing the CAR-T cell product, was approximately 7.5%. The patient and his or her family should be informed of this possibility.

**Post-apheresis**

The treatment with CAR-T cells for R/R ALL presents high rates of clinical response, with a prolonged period of remission in many patients. Different studies showed evidence of a correlation between low tumor burden prior to the infusion of CAR-T cells and decreased toxicity, with a better clinical response and OS. In a phase I study with 53 R/R ALL patients treated with anti-CD19-28z CAR-T cells, patients with a high tumor burden (≥5% of blasts in the bone marrow or extramedullary disease) had a higher incidence of CRS and neurotoxicity, and inferior long-term survival, when compared to patients with a low tumor burden. A retrospective study which included 15 institutions and 185 patients treated with tisagenlecleucel demonstrated that patients with a high tumor burden prior to the infusion of CAR-T cells had lower rates of complete response, OS and progression-free survival (PFS), when compared to patients with a low tumor burden or indetectable disease prior to the infusion.

The manufacturing of the cells takes approximately four weeks, from the reception of the apheresis product to the release of the genetically modified cells. During this period, the patient is vulnerable to the progression of the disease and the release of the genetically modified cells. During this period, the patient is vulnerable to the progression of the disease and other complications. Chemotherapy schemes, known as “bridging therapies” can be used between the apheresis and the infusion of CAR-T cells. Perica et al. evaluated different strategies of bridging therapy and the impact on the outcome after anti-CD19-28z CAR-T cells for adult patients with ALL.

The response to this treatment and a low tumor burden were correlated with favorable outcomes after the infusion of CAR-T cells. In addition, there was no significant difference in cell expansion in patients with persistent morphological disease, MRD-positive residual disease or in CR. There was no difference in the OS, CRs, and neurotoxicity grades 3 and 4 among patients who had received a chemotherapy scheme of high or low intensity, including monoclonal antibodies. However, bridging therapies based on high-intensity chemotherapy schemes were associated with higher rates of toxicity, such as severe infections (grades 3-4) and need for intensive clinical support in this period. There were no infectious complications in two patients who used blinatumomab and four patients on inotuzumab ozogamicin as bridging therapy. Of these six patients, three maintained complete remission following the treatment with CAR-T cells.

Prior to the CAR-T cell infusion, patients should receive lymphodepletion chemotherapy, which provides a favorable environment for the maintenance and expansion of CAR-T cells. Studies have shown that the improvement in the CAR-T cell expansion with lymphodepleting chemotherapy may be related to the elimination of regulatory T-cells and to the increase in cytokines, such as IL-7 and IL-15. There are diverse lymphodepleting chemotherapy schemes, including cyclophosphamide, fludarabine, bendamustine, etoposide and corporal irradiation. In a study with 30 R/R ALL patients, it was observed that patients who received a combination of cyclophosphamide and fludarabine presented a greater expansion of cells and longer PFS compared to those who received cyclophosphamide alone or cyclophosphamide and etoposide. Currently, cyclophosphamide plus fludarabine is the most commonly used lymphodepletion scheme prior to the infusion of CAR-T cells for ALL and administered, most of the time, up to two days prior to the infusion of CAR-T cells.

A summary of the recommendations for evaluation and selection for patients submitted to CAR-T cell therapy for ALL can be found in Table 1.

**ALL management post-CAR-T cell infusion**

Details of the clinical management post CAR-T cell infusion are addressed in the article I of the Consensus: “Structuring of centers for the clinical application and multidisciplinary management of patients submitted to CAR-T cell therapy”.

**Minimal residual disease**

The routine follow-up after CAR-T cell infusion beyond 28 days should follow the same recommendations as those for the post-HSCT recommendations. It is recommended that a monthly evaluation of MRD be made up to 6 months following the infusion, every 3 months up to one year and every 6 months following that, or sooner in case of clinical alterations or changing in blood counts. In Philadelphia positive ALL, the tyrosine kinase inhibitor is initiated after day 40, although no clear benefit has been demonstrated as to the prophylactic use versus initiation in the presence of positive MRD.

**Consolidation with HSCT**

Although CAR-T cell therapy shows high rates of remission for R/R ALL in children and adults, a significant portion of patients will relapse after the therapy. Consolidation with HSCT has been used in some patients by different clinical trials following remission (Table 2). For tisagenlecleucel in children and young adults, few patients included in the ELIANA trial (8/75) were submitted to transplant after achieving CR. In the real-world experience with tisagenlecleucel, only 16% of the patients who achieved a CR with CAR-T cells...
| Pre-apheresis evaluation/selection of patients | Post-apheresis evaluation/selection of patients and prior to lymphodepletion | Evaluation/selection of patients prior to the CAR-T cell infusion and post-lymphodepletion |
|---------------------------------------------|---------------------------------------------------------------------------------|---------------------------------------------------------------------------------|
| Confirmation of the presence of the CD19 antigen on the lymphoblasts – attention to the prior use of blinatumomab. | Evaluation of the ALL status (bone marrow tap and lumbar tap). The high tumor load increases the chance of CRS and ICANS. | Evaluation of the presence of rapidly progressive disease on the days preceding the infusion, as this increases the risk for CRS and the failure of the treatment. |
| Minimum necessary serology: hepatitis B and C and HIV. | Evaluation of the presence of active bacterial, fungal or viral infection. | - Absence of active bacterial, fungal or viral infection If there is active infection, the infusion should be postponed and the patient should receive complete treatment for the infection. The presence of active infection at the moment of the CAR-T infusion increases significantly the risk for CRS. |
| Patients with active infection are not eligible to receive CD19 CAR-T therapy. | Absence of active bacterial, fungal or viral infection. | - Absence of active GVHD – acute, grades II – IV, and extensively chronic. |
| Absence of active bacterial, fungal or viral infection. | | - Exclusion of the presence of gestation. |
| Minimal lymphocyte count: | | - Evaluation of the presence of new toxicities in target organs which may impact the capacity of the patient to receive chemotherapy (or subsequent CAR-T infusion). |
| total lymphocytes > 500/mm3 and CD3 > 150/mm3. | | - Special attention to the necessity for oxygen supplementation prior to the infusion and the presence of uncontrolled arrhythmias. |
| A low number of blood CD3 usually make various apheresis procedures necessary. | | - A minimum and variable washout period is recommended prior to the CAR-T infusion for the following therapies: |
| In patients who underwent allogeneic transplant, a minimum 12-week interval should be respected between the transplant and the apheresis. It is important not to have active acute or chronic host versus graft disease at the moment of apheresis and already suspended immunosuppressants, two weeks of calcineurin inhibitors cyclosporine/tacrolimus and one week of corticoid. | | - 3-day short-action proliferative agents (ex. hydroxyurea), tyrosine-kinase inhibitors and corticosteroids at a therapeutic dose. The use of hydrocortisone replacement or an equivalent at a dose less than 12mg/m²/day is permitted. The prescription of steroids for the management of adverse reactions during and following the CAR-T infusion. |
| The minimum washout period is variable and is recommended prior to the apheresis for the following therapies: | | - 5-day short-action growth factors (ex. G-CSF) and nilotinib. |
| - 1-day intrathecal cytarabine | | - 7-day vincristine, 6-MP, 6-TG, methotrexate (m2), cytarabine (>100mg/m²), non-pegylated asparaginase, intrathecal chemotherapy (methotrexate, cytarabine) |
| - 3-day short action anti proliferative (ex. hydroxyurea) | | - 14-day Other systemic chemotherapies, such as clofarabine, methotrexate (>25mg/m²), cytarabine (>100mg/m²) and Other agents (except those used in the lymphodepletion) and radiotherapy for sites beyond the central nervous system. |
| - 5-day short action growth factors (ex. hydroxyurea), tyrosine-kinase inhibitors and corticosteroids at a therapeutic dose. The use of hydrocortisone replacement or an equivalent at a dose less than 12mg/m²/day is permitted. The prescription of steroids for the management of adverse reactions during and following the CAR-T infusion. | | - 4-week PEG-asparaginase or immunosuppressants used in the treatment of GVHD. This last restriction is mainly to ensure that there be no relapse of GVHD prior to the CAR-T infusion. |
| - 6-week cranial radiotherapy and lymphodepletion | | - 6-week infusion of lymphocytes from the donor (DLI). |
| - 14-day systemic chemotherapy and, in general, long-action growth factors, imatinib, dasatinib, ponatinib and blinatumomab. | | - 8-week cranial radiotherapy and lytic agents for T-cells, such as ATG and alemtuzumab. |
| | | - Contact with the intensive therapy team. |
| - 12-week fludarabine and bendamustine | | - Verify with the pharmacy the availability of at least two doses of tocilizumab reserved for the patient for treatment of CRS. |
| - 4-week PEG-asparaginase and DLI | | |
| - 8-week clofarabine and cranial radiotherapy | | |
| - minimum of 8 weeks of lytic agents, such as ATG and campath. Some manufacturers suggest a longer washout (6 months) to be discussed case by case by the manufacturer’s medical team, if a smaller interval is possible | | |
| - 12-week fludarabine and bendamustine | | |
| - 6-month ATG or alemtuzumab. It is suggested to make contact with the CAR-T manufacturer to define if a shorter interval than this is possible. | | |
| - A minimally adequate function of the kidneys, liver, heart and lungs are indicated for the performance of apheresis. The patient must be previously evaluated by the apheresis team. An evaluation of the venous access is fundamental. In case of peripheral access in adults and most pediatric patients, the use of a central catheter of the dialysis type is recommended. | | |
| - It is important to verify that the patient is not pregnant and that that patient agrees to follow the effective contraception following the CAR-T cell infusion. Conception is not recommended following the CAR-T cell infusion, as the risk for the child is unknown. | | |

CAR-T: chimeric antigen receptor T cells. ALL: acute lymphoblastic leukemia, CRS: cytokine release syndrome, ICANS: immune effector cell-associated neurotoxicity syndrome, GVHD: graft versus host disease, DLI: donor lymphocyte infusion, G-CSF: granulocyte colony-stimulating factor, 6-MP: 6-mercaptopurine, 6-TG: 6-thioguanine, ATG: anti-thymocyte globulin

* Table based on references. 10,18,19,22-26.
| Author, year, clinical trial | Population Construct | N | Lymphodepletion | CR and CR with negative MRD | Outcome | Relapse | CD19 negative relapse | Allogeneic HSCT following the CAR-T | Observation |
|----------------------------|----------------------|---|-----------------|-----------------------------|---------|---------|---------------------|-----------------------------------|------------|
| Maude SL, ASCO 2016 Philadelphia UPenn | Pediatric FMC63-4-1BB-z | 59 | Cy 43% Flu Cy | 55/59 (93%) 88% | 12 months | SLD - 55% SG - 79% | 36% (20/55) 24% (13/55) | | |
| Maude SL, NEJM 2018 ELIANA trial Fase II | Pediatric AYA | 92 | Flu Cy (75) | 61/75 (81%) 81% | 12 months | SLD - 50% SG - 76% | 33% (20/61) 25% (15/61) 8/75 | 61% previous HSCT | |
| Lee DW, Lancet 2015/ Blood 2016 NCI Phase II | Pediatric AYA | 51 | Flu Cy | 31/51 (60,8%) 28/31 (90%) | 18 months | SLD - 49,5% | 29% (8/28) 18% (5/25) 21/28 | Significant improvement in survival with HSCT (= 0.0006) | |
| Gardner RA, Blood 2017 Seattle Fase I | Pediatric AYA | 45 | Flu Cy | 40/45 89% | 12 months | SLE - 50.8% SG - 69.5% | 45% (18/40) 18% (7/40) 8/75 | 62% previous HSCT | |
| Pasquini MC, Blood Adv 2020 | Pediatric AYA | 255 | Flu Cy | 85,5% 115/116 | 12 months | SLE - 54% SG - 77,2% | NA | 27.8% previous HSCT | |
| Hay KA, Blood 2019 Fred Hutchinson Fase I | Adult | 53 | 79% Flu Cy | 45/53 (85%) 100% | 12 months | SLE - 7,6 months SG - 12,9 months SLE - 6,1 months | 31% (9/29)* 7% (2/29)* 18/45 | 43 % previous HSCT | |
| Park JHF, NEJM 2018 Memorial Sloan-Kettering Fase I | Adult and pediatic SJ25C1-CD28-z | 53 | Flu Cy | 44/53 (83%) 32/48 (67%) | 12 months | SLE - 7,6 months SG - 12,9 months SLE - 6,1 months | 57% (25/44) 9% (4/44) 17/44 | 36 previous HSCT | |
| Pan J et al, Leukemia 2017 | Adult and pediatric 4-1BB-z | 42 | Flucy | 36/40 (90%) 34/40 (85%) | 12 months | SLE - 5,5 months SG - 7,6 months SLE - 12,9 months | 11/45 2 after HSCT | NA | 27/45 |
| Frey NV, JCO 2020 UPenn | Adult | 35 | 25 somente Cy | 24/35 (69%) 19 DRM - | 12 months | SLE - 6,9 months SG - 12,9 months | 8/18 | 3/8 | |
| Gu R et al, BMC 2020 | Pediatric and adult HI19u-4-1BB-ç | 22 | Flu Cy | 82% 18/18 100% | 12 months | SLE - 6,9 months SG - 12,9 months | 23/110 7/23 75/102 | 16/110 previous HSCT | |
| Zhang X et al, Blood Adv 2020 | Pediatric and adult 89 - 4-1BB-z | 110 | Flu Cy | 92.7% 87,3% | 12 months | SLE - 7,6 months SG - 12,9 months | 23/110 7/23 75/102 | 42% previous HSCT | |
| Shah BD, Lancet 2021 ZUMA-3 | Adult | 55 | Flu Cy | 39 (71%) 38/39 (99%) | 12 months | SLD - 58% | 12/39 | | |
| Shah N, JCO 2021 Fase I | Pediatric and Adult | 28 | Flu-Cy and others | 62% 90,3% | 4.8 years | SLD - 10.5 months | 9.5% after HSCT | 75% | SLE 5 years after HSCT - 62% |

* Reported in Turtle et al JCI 2016.

CTI: Car T cell infusion; AYA: adolescents and young adults; Flu: fludarabine; Cy: cyclophosphamide; LD: disease-free survival; SG: overall survival; SLE: event-free survival.
underwent transplan, which indicates that it is possible to attain long-term remission without HSCT. On the other hand, in clinical trials with CAR-T cells in adults, the consolidation with HSCT is almost always recommended.

Factors related to a better event-free survival (EFS) in adults who had received CAR-T cells included lower tumor burden, low LDH (< 210 U/L) and higher platelet count (> 100,000/mL) prior to the therapy, lymphodepletion with fludarabine, MRD-negative CR, and persistent B-cell aplasia (< 0.01% CD19+ B-cells in peripheral blood) within 28 days. Other factors, such as an elevated number of regulatory T-lymphocytes and extramedullary diseases are related to a longer EFS and OS. The factors described can be considered when making the decision on the HSCT after CAR-T cell therapy in adults.

Relapse

There is a significant risk of relapse following CAR-T cell treatment for B-ALL. As previously described (see details in “Patient selection, pre-infusion logistics, evaluation and management before CAR-T cells – pre-apheresis”), in patients who had received tisagenlecleucel, previous exposure to blinatumomab and a high disease burden correlate with an increased risk for relapse. The relapses following anti-CD19 CAR-T can be divided according to the CD19 status.

The CD19-positive relapses generally occur early following the infusion and are related to poor expansion of CAR-T cells and/or a short term persistence. Factors related to this type of relapse are a lower disease burden prior to lymphodepletion and a rapid loss of B-cell aplasia following the infusion. The CD19-negative relapses are described as “selection by immunological pressure” and can occur at any moment following the CAR-T cell therapy. Various mechanisms can result in the expression of CD19 variants and immunological escape, such as the CD19 locus deletion, de novo frameshift and missense mutations, and lower expression of SRSF3. The risk factors for CD19-negative relapse include high tumor burden (DRM ≥ 10−2) pre-lymphodepletion and detectable MRD 4 weeks after the infusion.

Conclusion

Anti-CD19 CAR-T cell therapy is a very promising immunotherapy for the treatment of R/R ALL. The treatment has well-defined phases: collection of autologous lymphocytes, bridging therapy, manufacture of genetically modified lymphocytes, lymphodepletion therapy and, finally, the infusion of the CAR-T cells. It is important that the team be attentive to the medications contraindicated prior to the apheresis for the collection of lymphocytes and/or prior to the infusion of the CAR-T cells, while being trained to recognize and manage the toxicities specific to the treatment. In the post-treatment follow-up, the CAR-T cell therapy can be considered either a definitive therapy for R/R B-ALL or bridge to HSCT. The rigorous monitoring of B-cell aplasia and MRD following the infusion can assist the team in determining the best moment to indicate the HSCT with the disease still in remission.

Conflicts of interest

The authors declare no conflicts of interest.

Supplementary materials

Supplementary material associated with this article can be found in the online version at doi:10.1016/j.htct.2021.09.002.

REFERENCES

1. Inaba H, Mullighan CG. Pediatric acute lymphoblastic leukemia. Haematologica. 2020;105(11):2524-39.
2. Tallen G, Ratei R, Mann G, Kaspers G, Niggl i F, Karachunsky A, et al. Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90. J Clin Oncol. 2010;28(14):2339-47.
3. Brasil. Ministério da Saúde Instituto Nacional do Cancer. INCA. Atlas de Mortalidade por Cancer [cited 2021 July] Available from: https://www.inca.gov.br/aplicativos/atlas-de-mortalidade-por-cancer
4. Greenbaum U, Mahadeo KM, Kebriaei P, Shpall EJ, Saini NY. Chimeric antigen receptor T-Cells in B-Acute lymphoblastic leukemia: state of the art and future directions. Front Oncol. 2020;10:1594. https://doi.org/10.3389/fonc.2020.01594. PMID: 32594622; PMCID: PMC7480185.
5. Locatelli F, Zugmaier G, Rizzari C, Morris JD, Gruhn B, Klingebiel T, et al. Effect of blinatumomab vs chemotherapy on event-free survival among children with high-risk first-relapse b-cell acute lymphoblastic leukemia: a randomized clinical trial. JAMA. 2021 Mar 2;325(9):843-54. https://doi.org/10.1001/jama.2021.0987. PMID: 33651091; PMCID: PMC7926287.
6. Brown PA, Ji L, Xu X, Devidas M, Hogan LE, Borowitz MJ, et al. Effect of Post Induction Therapy Consolidation with Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, adolescents and Young adults With first-relapse b-cell acute lymphoblastic leukemia: A randomized trial. JAMA. 2021 Mar 2;325(9):833-842. doi: 10.1001/jama.2021.0669.
7. Molina JC, Shah NN. CAR T cells better than BiTEs. Blood Adv. 2021 Jan 26;5(2):602-6.
8. Food and Drug Administration- FDA. USA. FDA approves tisagenlecleucel for b-cell ALL and tocilizumab for cytokine release syndrome [cited 2021 July 14]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tisagenlecleucel-b-cell-all-and-tocilizumab-cytokine-release-syndrome
9. European Medicines Agency. Kymriah. [cited 2021 July 14]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/kymriah
10. Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439-48.
11. Kymriah, INN-tisagenlecleucel. Anexo I. Resumo das caracteristicas do medicamento. [cited 2021 July 14]. Available from: https://www.ema.europa.eu/en/documents/product-information/kymriah-epar-product-information_pt.pdf
12. Package Insert – Kymriah. [cited 2021 July 14]. Available from: https://www.fda.gov/media/107296/download
13. Newman H, Leahy AE, Li Y, Liu H, Myer RM, DiNofia AM, et al. CD19-targeted chimeric antigen receptor (CAR) T cells in CNS
14. Pasquini MC, Hu ZH, Curran K, Laetsch T, Locke F, Rouce R, et al. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Adv. 2020;4(21):5414–24.

15. Frigault MJ, Dietrich J, Martinez-Lage M, Leick M, Choi DM, et al. Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia. Blood Rev. 2021;35:100848.

16. Shah BD, Ghobadi A, Oluwole OO, Logan AC, Boissel N, Cassady RD, et al. Kansagra AJ, Frey NV, Bar M, Laetsch TW, Carpenter PA, Savoldelli M, et al. Disease burden impacts outcomes in pediatric and young adult B-cell acute lymphoblastic leukemia after commercial tisagenlecleucel. Blood. 2020;136(Supplement 1):14–5.

17. Pillai V, Muradalharan K, Meng W, Bagashev A, Oldridge DA, Rosenthal J, et al. CAR T-cell therapy is effective for CD19(dim) B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy. Blood Adv. 2019;3(22):2339–49.

18. Deutche MC, Rajbanshi A, Yakhouchin K, Chevillon F, Cabannes-Hamy A, Méchinaud F, et al. Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia. Blood. 2021 May 17. https://doi.org/10.1182/blood.202102-1010440 [Epub ahead of print].

19. Krueger J, Bittencourt HNS, Rives S, Baruchel A, De Moerloose B, Peters C, et al. Tisagenlecleucel (Tisa) for relapsed/refractory (r/r) acute lymphoblastic leukemia (ALL): B2001X study focusing on r/r exposure to blinatumomab (BLINA) and inotuzumab (INO). J Clin Oncol. 2020;38(15_suppl). 10518–10518.

20. Fry TJ, Shah NN, Orentas RJ, Stetler-Stevenson M, Yuan CM, Ramakrishna S, et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med. 2018 Jan;24(1):20–6.

21. McGuirk J, Waller EK, Qayed M, Abhyankar S, Ericson S, Holman P, et al. Building blocks for institutional preparation of CTL019 delivery. Cytotherapy. 2017 Sep;19(9):1015–24.

22. Krell E, Laier S, Sauer S, Veelken K, Hennemann H, Schubert M, et al. Current challenges in providing good leukapheresis products for manufacturing of CAR-T cells for patients with relapsed/refractory NHL or ALL. Cells. 2020 May 15;9(5):1225.

23. Mahadeo KM, Khazal SJ, Abdel-Azim H, Fitzgerald JC, Tarasievic A, Bollard CM, et al. Chimeric antigen receptor T cells in hematologic malignancies: Pharmacotherapy. 2017;37(3):334–45.

24. Yokub-Agha I, Chabannon C, Bader P, Basak GW, Bonig H, Ciceri F, et al. Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). Haematologica. 2020;105(2):297–316.

25. Turtle CJ, Hanafi LA, Berger C, Gooley TA, Chiorino S, Hudecek M, et al. CD19 CAR-T cells of defined CD4+CD8+ composition in adult B-cell ALL patients. J Clin Invest. 2016;126(6):2123–8.

26. Mahadeo KM, Khazal SJ, Abdel-Azim H, Fitzgerald JC, Tarasievic A, Bollard CM, et al. Chimeric antigen receptor T cells in hematologic malignancies: Pharmacotherapy. 2017;37(3):334–45.

27. Centocor Inc. PK-Profil for CT019. 2017 Sep;19(9):1015–24.

28. Krell E, Laier S, Sauer S, Veelken K, Hennemann H, Schubert M, et al. Current challenges in providing good leukapheresis products for manufacturing of CAR-T cells for patients with relapsed/refractory NHL or ALL. Cells. 2020 May 15;9(5):1225.

29. Gardner RA, Finney O, Annesley C, Brakke H, Summers C, Leger K, et al. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood. 2017;129(25):3222–31.

30. Schuster SJ, Bishop MR, Tam CS, Waller ER, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45–56.

31. Perica K, Flynn J, Curran KJ, Riviere I, Wang X, Senechal B, et al. Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult acute lymphoblastic leukemia. Leukemia. 2021. https://doi.org/10.1038/s41375-021-01196-3. Epub ahead of print. PMID: 33686196; PMCID: PMC8423852.

32. Suryadevara CM, Desai R, Farber SH, Choi BD, Swartz AM, Shen SH, et al. Preventing Lck activation in CAR T cells confers treg resistance but requires 4-1BB signaling for them to persist and treat solid tumors in nonlymohdepleted hosts. Clin Cancer Res. 2019;25(1):358–68.

33. Shirato Y, Gauthier J, Hay KA, Voutsinas JM, Wu Q, Goeley T, et al. The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells. Blood. 2019;133(17):1865–76.

34. Gattinoni F, Finkelsztajn SE, Klebanoff CA, Antony PA, Palmer DC, Spiess PJ, et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med. 2005;202(7):907–12.

35. Thiandt S, Yokub-Agha I, Magro L, Trauet J, Coiteux V, Jouet JP, et al. Plasma levels of IL-7 and IL-15 in the first month after myeloablative BMT are predictive biomarkers of both acute GVHD and relapse. Bone Marrow Transplant. 2010;45(10):1546–52.

36. Shank BR, Do B, Sevin A, Chen SE, Neelapu SS, Horowitz SB. Chimeric antigen receptor T cells in hematologic malignancies. Pharmacotherapy. 2017;37(3):334–45.

37. Yokub-Agha I, Chabannon C, Bader P, Basak GW, Bonig H, Ciceri F, et al. Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). Haematologica. 2020;105(2):297–316.

38. Turtle CJ, Hanafi LA, Berger C, Gooley TA, Chiorino S, Hudecek M, et al. CD19 CAR-T cells of defined CD4+CD8+ composition in adult B-cell ALL patients. J Clin Invest. 2016;126(6):2123–8.

39. Mahadeo KM, Khazal SJ, Abdel-Azim H, Fitzgerald JC, Tarasievic A, Bollard CM, et al. Chimeric antigen receptor T cells in hematologic malignancies: Pharmacotherapy. 2017;37(3):334–45.

40. Centocor Inc. PK-Profil for CT019. 2017 Sep;19(9):1015–24.

41. Centocor Inc. PK-Profil for CT019. 2017 Sep;19(9):1015–24.

42. Dreyer T, De Filipp Z, et al. Tisagenlecleucel CAR T-cell therapy in second remission: a position statement of the European Workgroup for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). Haematologica. 2019;105(2):297–316.

43. Clé DV, Hirayama AV, Alencar AJ, Costa LJ, Feliciano JVP, Mattos ER, et al. Associação Brasileira de Hematologia, Hemoterapia e Terapia Célular consensus on genetically modified cells. I: Structuring centers for the multidisciplinary clinical administration and management of CAR-T cell therapy patients. Hematol Transfus Cell Ther. 2021. https://doi.org/10.1016/j.hct.2021.09.001. [Epub ahead of print].

44. Bruggemann M, Kotrova M. Minimal residual disease in adult ALL: technical aspects and implications for correct clinical interpretation. Blood Adv. 2017 Nov 28;1(25):2456–66.

45. Giebel S, Marks D, Boissel N, Baron F, Chiaretti S, Ciceri F, et al. Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2019 Jun;54(6):798–809.

46. Pfeifer H, Wassmann B, Bethge W, Dengler J, Bornhäuser M, Stadler m, et al. GMALL Study Group. Randomized comparison of prophylactic and minimal residual disease-triggered...
imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia. Leukemia. 2013 Jun;27(6):1254–62.

44. Cappell KM, Sherry RM, Yang JC, Goff SL, Vanasse DA, McIntyre L, et al. Long-term follow-up of anti-CD19 chimeric antigen receptor T-cell therapy. J Clin Oncol. 2020;38:3805–15. https://doi.org/10.1200/JCO.20.01467.

45. Jiang H, Hu Y, Mei H. Consolidative allogeneic hematopoietic stem cell transplantation after chimeric antigen receptor T-cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia: who? When? Why? Biomark Res. 2020 Nov 25;8(1):66.

46. Hay KA, Gauthier J, Hirayama AV, Voutsinas JM, Wu Q, Li D, et al. Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. Blood. 2019 Apr 11;133(15):1652–63. https://doi.org/10.1182/blood-2018-11-883710.

47. An F, Wang H, Liu Z, Wu F, Zhang J, Tao Q, et al. Influence of patient characteristics on chimeric antigen receptor T cell therapy in B-cell acute lymphoblastic leukemia. Nat Commun. 2020 Nov 23;11(1):5928.

48. Sotillo E, Barrett DM, Black KL, Bagashev A, Oldridge Sh, Wu G, et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov. 2015 Dec;5(12):1282–95. https://doi.org/10.1158/2159-8290.CD-15-1020. Epub 2015 Oct 29. PMID: 26516065; PMCID: PMC4670800.

49. Majzner RG, Mackall CL. Tumor antigen escape from CAR T-cell therapy. Cancer Discov. 2018 Oct;8(10):1219–26. https://doi.org/10.1158/2159-8290.CD-18-0442.

50. Maude SL. Efficacy of humanized CD19-targeted chimeric antigen receptor (CAR)-modified T cells in children with relapsed ALL. Maude SL, Barret DM, Rheingold SR, Aplenc R, Teachy DT eat al. ASCO 2016 abstract 3007.

51. Lee DW, Kochendorfer JN, Settler-Stevenson M, Cui YK, Delbrook C, Feldman SA, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015 Feb 7;385(9967):517–28.

52. Lee DW. Long-term outcomes following CD19 CAR T cell therapy for B-ALL are superior in patients receiving a fludarabine/cyclophosphamide preparative regimen and post-CAR hematopoietic stem cell transplantation. Blood. 2016;128(22):218. Abstract ASH 2016.

53. Pan J, Yang JF, Deng BP, Zhao XJ, Zhang X, Lin YH, et al. High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukaemia patients. Leukemia. 2017 Dec;31(12):2587–93.

54. Frey NV, Shaw PA, Hexner EO, Pequignot E, Gill S, Lugier SM, et al. Optimizing chimeric antigen receptor T-Cell therapy for adults with acute lymphoblastic leukemia. J Clin Oncol. 2020 Feb 10;38(5):415–22.

55. Gu R, Liu F, Zou D. Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia. J Hematol Oncol. 2020;122. https://doi.org/10.1186/s13045-020-00953-8.

56. Zhang X, Lu X-a, Yang J, Zhang G, Li J, Song L, et al. Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features. Blood Advances. 2020 May 26;4(10):2325–38. https://doi.org/10.1182/bloodadvances.2020001466. 2020.

57. Shah NN, Lee DW, Yates B, Yuan CM, Shalabi H, Martin S, et al. Long-term follow-Up of CD19-CAR T-cell therapy in children and young adults with B-ALL. J Clin Oncol. 2021 May 20;39(15):1650–9. https://doi.org/10.1200/JCO.20.02262. Epub 2021 Mar 25. PMID: 33764809; PMCID: PMC8274806.